Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2023 01:00 ET | Source: argenx SE

argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

July 20, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
July 19, 2023 17:58 ET | Source: argenx SE

argenx announces full exercise of underwriters’ option to purchase additional ADSs

Regulated information — Inside information July 19, 2023, 11:58 PM CETJuly 19, 2023, 5:58 PM ET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
July 18, 2023 21:30 ET | Source: argenx SE

argenx raises $1.1 billion in gross proceeds in a global offering

Regulated information — Inside information July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology...
July 17, 2023 16:01 ET | Source: argenx SE

argenx announces launch of proposed global offering

Regulated information — Inside information argenx announces launch of proposed global offering July 17, 2023 Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global...
July 17, 2023 01:00 ET | Source: argenx SE

argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role...
June 30, 2023 09:39 ET | Source: argenx SE

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

First-and-only approved FcRn antagonist for gMG patients by NMPA68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of...
June 20, 2023 18:12 ET | Source: argenx SE

argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis

VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) With this approval, argenx broadens innovative gMG product offering and demonstrates...
June 20, 2023 01:00 ET | Source: argenx SE

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

Independent Data Monitoring Committee recommended study continuation based on the favorable safety profile observed in the first dose cohortEarly efficacy signals support proof-of-concept of...
May 31, 2023 01:00 ET | Source: argenx SE

argenx to Present at Upcoming Investor Conferences

May 31, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
May 04, 2023 01:00 ET | Source: argenx SE

argenx Reports First Quarter 2023 Financial Results and Provides Business Update

$218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART received marketing authorization in Israel through partnership with Medison88 events achieved in...